Overview

Gender

male

He also acted as the company’s Chairman from November 2009 until March 2011, when the company was acquired by Amgen for up to $1bn ($425m upfront). BioVex (now a subsidiary of Amgen) is based in Woburn, MA, USA and Abingdon, UK and develops biologics for solid tumours and prophylactic vaccines for infectious diseases.

The Company’s lead program is completing Phase III testing for metastatic melanoma (study fully enrolled). Philip’s key responsibilities and achievements at Biovex include the successfully implemented exit strategy; the sale to Amgen represented one of the largest takeovers of a private VC backed biotech company in recent years.

In 2005, Philip established Biovex’ US operations from scratch; recruiting the entire US senior management team (outside the CTO) whilst setting up all key functions including commercial capabilities. Arriving as the first employee in the US he grew the Company to 70 employees in Woburn, MA while retaining 30 in Abingdon, UK.

Over the years, Philip executed five major private equity financings involving blue chip international investor syndicates totaling more than $160m including the second largest biotech VC raise of 2009 at $70m. He also oversaw the building of a launch grade manufacturing facility to zero default timelines and led his team through the agreement of a SPA with the FDA on the design of a pivotal study which commenced and was recruited on projected timeframes. Philip recently joined the Board of Directors of Oxyrane as Chairman.